Puma Biotechnology, Inc. - News Releases

Get News Alerts by RSS

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

12/14/2017

Puma Biotechnology Added to NASDAQ Biotechnology Index

12/13/2017

Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

12/12/2017

Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer

12/11/2017

Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings

12/06/2017

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium

11/22/2017

Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia

11/13/2017

Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology

11/09/2017

Puma Biotechnology Reports Third Quarter 2017 Financial Results

11/08/2017

Puma Biotechnology to Present at Stifel Healthcare Conference

11/02/2017

Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance

10/31/2017

Puma Biotechnology to Present at Credit Suisse Healthcare Conference

10/26/2017

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

09/18/2017

Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference

09/08/2017

Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET Trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress

08/31/2017

Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference

08/30/2017

Puma Biotechnology Announces Publication of Abstracts for ESMO 2017

08/25/2017

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

08/09/2017

Puma Biotechnology Reports Second Quarter 2017 Financial Results

08/02/2017

Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP)

07/31/2017

Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in the United States

07/17/2017

U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

07/06/2017

Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial

06/03/2017

Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 Trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting

05/31/2017

Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference

05/24/2017

Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib

05/22/2017

Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting

05/17/2017

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting

05/10/2017

Puma Biotechnology Reports First Quarter 2017 Financial Results

05/09/2017

Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference

04/17/2017

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

04/04/2017

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting

04/02/2017

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting

04/02/2017

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting

04/02/2017

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers

03/02/2017

Puma Biotechnology to Present at Cowen’s Health Care Conference

03/01/2017

Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017

03/01/2017

Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272

03/01/2017

Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results

02/14/2017

Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference

02/08/2017

Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference

01/06/2017

Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients

01/03/2017

Puma Biotechnology to Present at J.P. Morgan Healthcare Conference